Disposition of Participants

	Placebo		Xanomeline Low Dose		Xanomeline High Dose	
	n	(%)	n	(%)	n	(%)
Participants in population	86		84		84	
Completed	58	67.4	25	29.8	27	32.1
Discontinued	28	32.6	59	70.2	57	67.9
Adverse Event	8	9.3	44	52.4	40	47.6
Death	2	2.3	1	1.2	0	0.0
I/E Not Met	1	1.2	0	0.0	2	2.4
Lack of Efficacy	3	3.5	0	0.0	1	1.2
Lost to Follow-up	1	1.2	1	1.2	0	0.0
Physician Decision	1	1.2	0	0.0	2	2.4
Protocol Violation	1	1.2	1	1.2	1	1.2
Sponsor Decision	2	2.3	2	2.4	3	3.6
Withdrew Consent	9	10.5	10	11.9	8	9.5

ANCOVA of Change from Baseline Glucose (mmol/L) at Week 24
LOCF
Efficacy Analysis Population

	Baseline		Week 24		Change from Baseline		
Treatment	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	LS Mean (95% CI)[a]
Placebo	79	5.7 (2.23)	57	5.7 (1.83)	57	-0.1 (2.68)	0.07 (-0.27, 0.41)
Xanomeline Low Dose	79	5.4 (0.95)	26	5.7 (1.26)	26	0.2 (0.82)	-0.11 (-0.45, 0.23)
Xanomeline High Dose	74	5.4 (1.37)	30	6.0 (1.92)	30	0.5 (1.94)	0.40 (0.05, 0.75)

Pairwise Comparison	Difference in LS Mean (95% CI)[a]	p-Value
Xanomeline Low Dose - Placebo	-0.17 (-0.65, 0.30)	0.757
Xanomeline High Dose - Placebo	0.33 (-0.16, 0.82)	0.381

[a]Based on an ANCOVA model after adjusting baseline value. LOCF approach is used to impute missing values.
ANCOVA = Analysis of Covariance, LOCF = Last Observation Carried Forward
CI = Confidence Interval, LS = Least Squares, SD = Standard Deviation

Kaplan-Meier Plot for Time to First Dermatologic Event by Treatment Group
All Participants



footnote

[datasource: adam-adtte]